文献速递妇科

铂类单药与铂类双药同步放化疗治疗局部晚期宫颈癌:随机对照试验的荟萃分析

Platinum single-agent vs. platinum-based doublet agent concurrent chemoradiotherapy for locally advanced cervical cancer: A meta-analysis of randomized controlled trials.
PubMed 文献 · Gynecol Oncol · 2019-04-18

该荟萃分析纳入7项随机对照试验共1503例局部晚期宫颈癌患者,比较放疗同步铂类双药化疗与放疗同步铂类单药化疗的疗效与不良事件。结果显示双药方案显著改善总生存(HR 0.75,95%CI 0.60-0.94,p=0.01)和无进展生存(HR 0.78,95%CI 0.65-0.94,p=0.01),但3或4级呕吐和血小板减少更常见。作者结论为在耐受良好的前提下,双药方案较单药方案改善生存。

要点

  • 双药同步放化疗较单药显著改善总生存(HR 0.75,95%CI 0.60-0.94,p=0.01)。
  • 双药同步放化疗较单药显著改善无进展生存(HR 0.78,95%CI 0.65-0.94,p=0.01)。
  • 双药组3或4级呕吐(RR 3.19)和血小板减少(RR 2.75)更常见。

核心结论

  • 在耐受良好的前提下,放疗同步铂类双药化疗较放疗同步铂类单药化疗改善局部晚期宫颈癌患者的生存。

研究设计与样本

  • 系统综述与累积荟萃分析,全面检索Medline、Embase、Cochrane图书馆、中国知网、万方数据库和维普数据库。
  • 纳入7项随机对照试验,共1503例患者,采用固定效应或随机效应模型,使用RevMan 5.2进行荟萃分析。
  • 主要终点为总生存和无进展生存,以风险比(HR)和95%置信区间(95%CI)报告。

主要发现

  • 与放疗同步顺铂单药化疗相比,放疗同步铂类双药化疗显著改善总生存(HR 0.75,95%CI 0.60-0.94,p=0.01)。
  • 与放疗同步顺铂单药化疗相比,放疗同步铂类双药化疗显著改善无进展生存(HR 0.78,95%CI 0.65-0.94,p=0.01)。
  • 3或4级呕吐在双药化疗组更常见(RR=3.19,95%CI 1.85-5.49,p<0.0001)。
  • 血小板减少在双药化疗组更常见(RR=2.75,95%CI 1.39-5.44,p=0.004)。
  • 泌尿系统毒性在双药化疗组有更高趋势(RR=4.58,95%CI 1.00-20.89,p=0.05)。

临床怎么用

  • 作者结论认为,在耐受良好的前提下,放疗同步铂类双药化疗较放疗同步铂类单药化疗改善局部晚期宫颈癌患者的生存。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: This study compared treatment outcomes and adverse events in patients with locally advanced cervical cancer undergoing radiotherapy (RT) with concurrent platinum-based doublet therapy vs. RT plus platinum single-agent therapy. The main outcomes were progression-free survival (PFS), overall survival (OS), and the occurrence of adverse events. METHODS: We comprehensively searched Medline, Embase, the Cochrane Library, China National Knowledge Web, Wanfang Database, and VIP database, and performed a systematic review and cumulative meta-analysis of all randomized controlled trials (RCTs) by using the fixed-effect or random-effect models. The primary endpoints were OS and PFS, reported as hazard ratios (HRs) and 95% confidence intervals (95% CIs). The meta-analysis was performed with RevMan 5.2. RESULTS: Seven randomized trials including 1503 patients were identified. The meta-analysis showed that, for locally advanced cervical cancer, concurrent RT with platinum-based doublet chemotherapy significantly improved the OS (HR 0.75, 95% CI 0.60-0.94, p = 0.01) and the PFS (HR 0.78, 95% CI 0.65-0.94,p = 0.01) compared to RT with cisplatin monotherapy. Grade 3 or 4 vomiting (related ratio [RR] = 3.19, 95% CI 1.85-5.49, p < 0.0001) and thrombocytopenia (RR = 2.75, 95% CI 1.39-5.44, p = 0.004) occurred more frequently in the polychemotherapy arm. The incidence of urinary system toxicity tended to be higher in the polychemotherapy arm (RR = 4.58, 95% CI 1.00-20.89, p = 0.05). CONCLUSIONS: Under the premise of good tolerance, RT plus platinum-based doublet therapy improves survival compared to RT plus platinum single-agent therapy in patients with locally advanced cervical cancer.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Ma S, Wang J, Han Y, et al. Platinum single-agent vs. platinum-based doublet agent concurrent chemoradiotherapy for locally advanced cervical cancer: A meta-analysis of randomized controlled trials. Gynecol Oncol. 2019. PMID: 31005286. doi:10.1016/j.ygyno.2019.04.013

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。